Oricell Therapeutics Announces $70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
“We are deeply grateful for the strong vote of confidence from our investors,” said Dr. Helen Yang, Chairlady and CEO of Oricell Therapeutics. “Oricell will continue to push forward the global clinical advancement of our pipeline, as well as continuous R&D of in vivo products and new technologies. Leveraging our deep technical expertise, policy tailwind and expanding market opportunities, we are able to accelerate the development of our CAR-Ts in the clinic at full speed. Our mission is to bring efficacious and affordable cell therapies to cancer patients worldwide with the hope of cure. By doing that, we aim to become a leading global immunotherapy enterprise.”
Share:
More News
Dr. Michael Ge, CEO of Kelun-Biotech said, “We are delighted to see the acceptance of the fifth indication application for sac-TMT. Compared to immunotherapy alone, the ADC combination with KEYTRUDA® as first-line treatment for PD-L1-positive NSCLC has achieved not only positive results in PFS, but also a trend toward benefit
“We are excited to work with Merck to advance this promising investigational combination in RAS-driven cancers,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “RAS mutations activate the RAS/MAPK pathway and promote an immunosuppressive environment. Non-clinical data suggest that targeting the pathway with ERAS-0015 may complement PD-1 blockade
“Dosing the first patient in the ASPENOVA Phase 3 clinical trial represents a significant milestone in our development of azenosertib for patients with platinum-resistant ovarian cancer,” said Ingmar Bruns, M.D., Chief Medical Officer of Zentalis. “With DENALI Part 2 progressing toward a year-end readout that may support accelerated approval and
“The depth, durability, and consistency of responses observed across both the total population and BTKi-treated subsets underscore iopofosine’s potential as a meaningful new treatment option in WM and differentiate it from currently available therapies,” said Jarrod Longcor, chief operating officer of Cellectar Biosciences. “With the completion of at least 12-month